Sequence analysis of 131 human brains has revealed the mutagenesis processes that take place throughout life, from development to senescence. In a new study published in the July 29, 2022, issue of Science, the authors described how high rates of brain somatic mutations (what they call hypermutability) correlated with age. Their work includes certain neuropsychiatric diseases, where they found some genetic signatures that could be used for an early clinical diagnosis of different pathologies. Read More
Researchers from Cantargia and Johns Hopkins University School of Medicine presented data from a preclinical study evaluating an IL-1 receptor accessory protein (IL-1RAP)-blocking antibody, CAN-10, in a model of acute coxsackievirus B3 (CVB3) myocarditis. Read More
Jing Medicine Technology has described new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a mothers against decapentaplegic homolog 3 (SMAD3)-targeting moiety through a linker reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and autoimmune disease. Read More
Oncobix has discovered Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of multiple sclerosis, inflammation, urticaria, systemic lupus erythematosus, allergy, rheumatoid arthritis, asthma and leukemia. Read More
A research team at Shanghai University and Shaanxi University of Chinese Medicine has discovered a novel lipid-lowering compound with hepatoprotective effects. Read More
3B Pharmaceuticals has divulged conjugates comprising fibroblast activation protein alpha (FAPalpha) inhibitors covalently linked to radiolabeled chelating agents through a linker acting as single-photon emission computed tomography (SPECT)/CT imaging agents reported to be useful for the diagnosis and treatment of cancer. Read More
Cambridge Enterprise and European Molecular Biology Laboratory have presented new peptides derived from full-length factor V (FV) protein acting as T-cell activation inhibitors reported to be useful for the treatment of inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, psoriasis, vasculitis, idiopathic pulmonary fibrosis, vitiligo and lupus nephritis, among other disorders. Read More
The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have discovered isoindolinone aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatement of cancer and fibrosis. Read More
Ozette Technologies has announced USD 26 million in Series A funding. The company is focused on artificial intelligence (AI)-powered single-cell immune discovery technology. Read More
Ipsen and Marengo Therapeutics have entered into a strategic partnership to advance two of Marengo's preclinical STAR (Selective T Cell Activation Repertoire) platform-generated candidates into the clinic. Read More
The FDA has approved Eccogene's IND application to commence a phase I trial of the company's thyroid hormone receptor (THR) agonist ECC-4703 in the U.S. Read More
Using a knock-in mouse model of Brugada syndrome (BrS) with an SCN5A mutation identified in multiple BrS families (Scn5aG1746R/+), a team of scientists from various research institutions evaluated the effects of upregulation of MOG1 (ran guanine nucleotide release factor, RanGNRF) via adeno-associated virus serotype 9 (AAV9) vector delivery on BrS features. Read More
